Pomerantz Law Firm Files Class Action Suit Against Atara Biotherapeutics Over Securities Fraud Allegations
In a significant legal development, Pomerantz LLP has announced the initiation of a class action lawsuit against Atara Biotherapeutics, Inc. and several of its top executives. The class action, registered in the U.S. District Court for the Central District of California under the docket number 26-cv-03083, addresses claims from all individuals and entities that purchased Atara securities during the defined period from May 20, 2024, to January 9, 2026. The plaintiffs are seeking restitution for losses attributed to violations of federal securities laws and have invoked provisions of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a), along with Rule 10b-5.
Investors who acquired Atara shares within this timeframe are advised that they have until May 22, 2026, to petition the Court to be appointed as Lead Plaintiff in the case. Those interested can obtain a copy of the Complaint through Pomerantz’s website or contact Danielle Peyton directly for further inquiries. Encouraged to provide their email address, phone number, and pertinent investment details, potential plaintiffs can pursue their options through this legal channel.
Atara Biotherapeutics specializes in creating therapies for patients afflicted by solid tumors, hematologic malignancies, and autoimmune disorders, both in the United States and the United Kingdom. Their flagship development project is tabelecleucel, also known as tab-cel or EBVALLO, a T-cell immunotherapy aimed particularly at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
The Company has established a partnership with Pierre Fabre Médicament, a division within the broader Pierre Fabre Laboratories group, for tabelecleucel’s commercialization. This relationship is critical as Atara relies heavily on milestone payments from Pierre Fabre, which are contingent on achieving specified development goals for tabelecleucel. Such funding is essential to support Atara's business operations and regulatory approval efforts related to this therapy.
In May 2024, Atara made a pivotal move by submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel, targeting adult and pediatric patients aged two years and older with EBV+ PTLD who have undergone one or more previous treatments. This application was reportedly backed by results from their Phase 3 ALLELE study, which evaluated the efficacy of tabelecleucel.
However, the lawsuit alleges that throughout the Class Period, Atara's executives made significant false and misleading representations regarding the company's operations and potential. Specifically, assertions were allegedly made regarding the favorable regulatory prospects for tabelecleucel, despite existing manufacturing issues and deficiencies connected with the ALLELE study that, according to the allegations, would undermine the likelihood of FDA approval.
As the truth began to surface, particularly following an announcement on January 16, 2025, where Atara revealed it received a Complete Response Letter (CRL) from the FDA concerning the tabelecleucel BLA, the company's stock saw a dramatic drop. This CRL indicated that Atara's application would not be approved in its current format due to adverse findings from a pre-license inspection of the third-party manufacturing facility associated with the EBVALLO treatment. Following this revelation, Atara's stock price plummeted by over 40%.
Further pressure mounted when, on January 21, 2025, Atara disclosed that the FDA had enforced a clinical hold on its Investigational New Drug applications due to GMP compliance issues also linked to the manufacturing concerns raised in their CRL, prompting an additional decrease in the company's stock value.
The saga continued when Atara faced another CRL from the FDA on January 12, 2026, indicating that its clinical trial design and analytics were inadequate for establishing the expected evidence of effectiveness, causing a staggering drop in stock value yet again.
Pomerantz Law Firm, recognized for its significant contributions to corporate and securities litigation, aims to ensure accountability for the alleged corporate misconduct and restore losses incurred by affected investors. Individuals seeking further information or wishing to participate in the class action are urged to visit Pomerantz's website or contact the firm directly.
This case highlights the ongoing challenges within the biopharmaceutical sector, where investor confidence can be profoundly shaken by undisclosed operational risks and regulatory hurdles. As the situation evolves, affected stakeholders will be closely watching how these developments unfold in the judicial process.
Investors who acquired Atara shares within this timeframe are advised that they have until May 22, 2026, to petition the Court to be appointed as Lead Plaintiff in the case. Those interested can obtain a copy of the Complaint through Pomerantz’s website or contact Danielle Peyton directly for further inquiries. Encouraged to provide their email address, phone number, and pertinent investment details, potential plaintiffs can pursue their options through this legal channel.
Atara Biotherapeutics specializes in creating therapies for patients afflicted by solid tumors, hematologic malignancies, and autoimmune disorders, both in the United States and the United Kingdom. Their flagship development project is tabelecleucel, also known as tab-cel or EBVALLO, a T-cell immunotherapy aimed particularly at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
The Company has established a partnership with Pierre Fabre Médicament, a division within the broader Pierre Fabre Laboratories group, for tabelecleucel’s commercialization. This relationship is critical as Atara relies heavily on milestone payments from Pierre Fabre, which are contingent on achieving specified development goals for tabelecleucel. Such funding is essential to support Atara's business operations and regulatory approval efforts related to this therapy.
In May 2024, Atara made a pivotal move by submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel, targeting adult and pediatric patients aged two years and older with EBV+ PTLD who have undergone one or more previous treatments. This application was reportedly backed by results from their Phase 3 ALLELE study, which evaluated the efficacy of tabelecleucel.
However, the lawsuit alleges that throughout the Class Period, Atara's executives made significant false and misleading representations regarding the company's operations and potential. Specifically, assertions were allegedly made regarding the favorable regulatory prospects for tabelecleucel, despite existing manufacturing issues and deficiencies connected with the ALLELE study that, according to the allegations, would undermine the likelihood of FDA approval.
As the truth began to surface, particularly following an announcement on January 16, 2025, where Atara revealed it received a Complete Response Letter (CRL) from the FDA concerning the tabelecleucel BLA, the company's stock saw a dramatic drop. This CRL indicated that Atara's application would not be approved in its current format due to adverse findings from a pre-license inspection of the third-party manufacturing facility associated with the EBVALLO treatment. Following this revelation, Atara's stock price plummeted by over 40%.
Further pressure mounted when, on January 21, 2025, Atara disclosed that the FDA had enforced a clinical hold on its Investigational New Drug applications due to GMP compliance issues also linked to the manufacturing concerns raised in their CRL, prompting an additional decrease in the company's stock value.
The saga continued when Atara faced another CRL from the FDA on January 12, 2026, indicating that its clinical trial design and analytics were inadequate for establishing the expected evidence of effectiveness, causing a staggering drop in stock value yet again.
Pomerantz Law Firm, recognized for its significant contributions to corporate and securities litigation, aims to ensure accountability for the alleged corporate misconduct and restore losses incurred by affected investors. Individuals seeking further information or wishing to participate in the class action are urged to visit Pomerantz's website or contact the firm directly.
This case highlights the ongoing challenges within the biopharmaceutical sector, where investor confidence can be profoundly shaken by undisclosed operational risks and regulatory hurdles. As the situation evolves, affected stakeholders will be closely watching how these developments unfold in the judicial process.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.